Kahn, J. S. Epidemiology of human metapneumovirus. Clin. Microbiol. Rev. 19, 546–557 (2006).
Li, Y. et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob. Health 7, e1031–e1045 (2019).
Wang, X. et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob. Health 9, e33–e43 (2021).
Munro, A. P. S., Martinón-Torres, F., Drysdale, S. B. & Faust, S. N. The disease burden of respiratory syncytial virus in infants. Curr. Opin. Infect. Dis. 36, 379–384 (2023).
Huang, J., Diaz, D. & Mousa, J. J. Antibody epitopes of pneumovirus fusion proteins. Front. Immunol. 10, 2778 (2019).
Kinder, J. T. et al. Respiratory syncytial virus and human metapneumovirus infections in three-dimensional human airway tissues expose an interesting dichotomy in viral replication, spread, and inhibition by neutralizing antibodies. J. Virol. 94, 10.1128/jvi.01068–20 (2020).
Panda, S., Mohakud, N. K., Pena, L. & Kumar, S. Human metapneumovirus: review of an important respiratory pathogen. Int. J. Infect. Dis. 25, 45–52 (2014).
Pitzer, V. E. et al. Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLOS Pathog. 11, e1004591 (2015).
Baker, R. E. et al. Epidemic dynamics of respiratory syncytial virus in current and future climates. Nat. Commun. 10, 5512 (2019).
Fisman, D. Seasonality of viral infections: mechanisms and unknowns. Clin. Microbiol. Infect. 18, 946–954 (2012).
Moriyama, M., Hugentobler, W. J. & Iwasaki, A. Seasonality of respiratory viral infections. Annu. Rev. Virol. 7, 83–101 (2020).
Bhattacharyya, S., Gesteland, P. H., Korgenski, K., Bjørnstad, O. N. & Adler, F. R. Cross-immunity between strains explains the dynamical pattern of paramyxoviruses. Proc. Natl. Acad. Sci. USA 112, 13396–13400 (2015).
Shrestha, S., King, A. A. & Rohani, P. Statistical inference for multi-pathogen systems. PLOS Comput. Biol. 7, e1002135 (2011).
Trepat, K., Gibeaud, A., Trouillet-Assant, S. & Terrier, O. Exploring viral respiratory coinfections: shedding light on pathogen interactions. PLOS Pathog. 20, e1012556 (2024).
Geiser, J. et al. RSV and HMPV infections in 3D tissue cultures: mechanisms involved in virus-host and virus-virus interactions. Viruses 13, 139 (2021).
Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439–443 (2013).
Wen, X. et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017).
Cabán, M. et al. Cross-protective antibodies against common endemic respiratory viruses. Nat. Commun. 14, 798 (2023).
Más, V. et al. Engineering, structure and immunogenicity of the human metapneumovirus F protein in the postfusion conformation. PLOS Pathog. 12, e1005859 (2016).
Rappazzo, C. G. et al. Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. Immunity 55, 1710–1724.e8 (2022).
Wyde, P. R., Chetty, S. N., Jewell, A. M., Boivin, G. & Piedra, P. A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir. Res. 60, 51–59 (2003).
Yang, Q. et al. Assessing population-level target product profiles of universal human influenza A vaccines. Epidemics 48, 100776 (2024).
Jiang, H. et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 10, 619–628 (2021).
Wang, J. et al. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine 39, 3319–3323 (2021).
Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962–1973 (2011).
Kareiva, P. Exclusion experiments and the competitive release of insects feeding on collards. Ecology 63, 696–704 (1982).
Langedijk, A. C. & Bont, L. J. Respiratory syncytial virus infection and novel interventions. Nat. Rev. Microbiol. 21, 734–749 (2023).
Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837–846 (2022).
Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451–1464 (2023).
Ares-Gómez, S. et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect. Dis. 24, 817–828 (2024).
Cong, B. et al. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis. Lancet Infect. Dis. 24, 361–374 (2023).
Chow, E. J., Uyeki, T. M. & Chu, H. Y. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat. Rev. Microbiol. 21, 195–210 (2023).
Saad-Roy, C. M. et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science 370, 811–818 (2020).
White, L. J., Waris, M., Cane, P. A., Nokes, D. J. & Medley, G. F. The transmission dynamics of groups a and b human respiratory syncytial virus (HRSV) in England and Wales and Finland: seasonality and cross-protection. Epidemiol. Infect. 133, 279–289 (2005).
Google LLC. COVID-19 Community Mobility Report. https://www.google.com/covid19/mobility?hl=en.
Baker, R. E. et al. Long-term benefits of nonpharmaceutical interventions for endemic infections are shaped by respiratory pathogen dynamics. Proc. Natl. Acad. Sci. USA 119, e2208895119 (2022).
Dalziel, B. D. et al. Persistent chaos of measles epidemics in the prevaccination United States caused by a small change in seasonal transmission patterns. PLOS Comput. Biol. 12, e1004655 (2016).
Madewell, Z. J. et al. Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019. Influenza Other Respir. Viruses 17, e13212 (2023).
Zhang, L. et al. Statistical analysis of common respiratory viruses reveals the binary of virus-virus interaction. Microbiol. Spectr. 11, e00019–23 (2023).
Nickbakhsh, S. et al. Virus–virus interactions impact the population dynamics of influenza and the common cold. Proc. Natl. Acad. Sci. USA 116, 27142–27150 (2019).
Horemheb-Rubio, G. et al. Respiratory viruses dynamics and interactions: ten years of surveillance in central Europe. BMC Public Health 22, 1167 (2022).
Domenech de Cellès, M., Goult, E., Casalegno, J.-S. & Kramer, S. C. The pitfalls of inferring virus–virus interactions from co-detection prevalence data: application to influenza and SARS-CoV-2. Proc. R. Soc. B Biol. Sci. 289, 20212358 (2022).
Chin, T., Foxman, E. F., Watkins, T. A. & Lipsitch, M. Considerations for viral co-infection studies in human populations. mBio 15, e00658–24 (2024).
Kucharski, A. J., Andreasen, V. & Gog, J. R. Capturing the dynamics of pathogens with many strains. J. Math. Biol. 72, 1–24 (2016).
Williams, T. C. et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants: results of a prospective, multi-centre, test-negative study https://papers.ssrn.com/abstract=5184994 (2025).
Mazur, N. I. et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect. Dis. 18, e295–e311 (2018).
Gunatilaka, A. & Giles, M. L. Maternal RSV vaccine development. Where to from here? Hum. Vacc. Immunother. 17, 4542–4548 (2021).
Le, H., Gidding, H., Blyth, C. C., Richmond, P. & Moore, H. C. Pneumococcal conjugate vaccine are protective against respiratory syncytial virus hospitalizations in infants: a population-based observational study. Open Forum Infect. Dis. 10, ofad199 (2023).
Rybak, A. et al. Age-specific resurgence in invasive pneumococcal disease incidence in the COVID-19 pandemic era and its association with respiratory virus and pneumococcal carriage dynamics: a time-series analysis. Clin. Infect. Dis. 78, 855–859 (2024).
Lees, E. A. et al. Epidemiology and management of pediatric group A streptococcal pneumonia with parapneumonic effusion: an observational study. Pediatr. Infect. Dis. J. 43, 841–850 (2024).
Savic, M., Penders, Y., Shi, T., Branche, A. & Pirçon, J.-Y. Respiratory syncytial virus disease burden in adults aged 60+ years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir. Viruses 17, e13031 (2023).
Terstappen, J. et al. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect. Dis. 24, e747–e761 (2024).
Chua, H. et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 31, 43–64 (2020).
Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543–546 (1986).
Wilkins, D. et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat. Med. 29, 1172–1179 (2023).
Yamin, D. et al. Vaccination strategies against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 113, 13239–13244 (2016).
Moe, N. et al. Comparing human metapneumovirus and respiratory syncytial virus: viral co-detections, genotypes and risk factors for severe disease. PLOS One 12, e0170200 (2017).
Ordás, J. et al. Role of metapneumovirus in viral respiratory infections in young children. J. Clin. Microbiol. 44, 2739–2742 (2006).
Cui, A. et al. Comparative analysis of the clinical and epidemiological characteristics of human influenza virus versus human respiratory syncytial virus versus human metapneumovirus infection in nine provinces of China during 2009–2021. J. Med. Virol. 94, 5894–5903 (2022).
Arbetter, D. et al. Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody Nirsevimab immunization versus placebo: analysis from a phase 3 randomized clinical trial (MELODY). Clinical Infectious Diseases ciae596 https://doi.org/10.1093/cid/ciae596 (2024).
Curns, A. T. et al. Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020. Pediatrics 153, e2023062574 (2024).
Gil-Prieto, R., Gonzalez-Escalada, A., Marín-García, P., Gallardo-Pino, C. & Gil-de Miguel, A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities. Medicine 94, e831 (2015).
Dankwa, E. A., Brouwer, A. F. & Donnelly, C. A. Structural identifiability of compartmental models for infectious disease transmission is influenced by data type. Epidemics 41, 100643 (2022).
Saucedo, O. et al. Comparative analysis of practical identifiability methods for an SEIR model. AIMS Math. 9, 24722–24761 (2024).
Park, S. W. et al. Predicting the impact of non-pharmaceutical interventions against COVID-19 on Mycoplasma pneumoniae in the United States. Epidemics 49, 100808 (2024).
Holmdahl, I. et al. Differential impact of COVID-19 non-pharmaceutical interventions on the epidemiological dynamics of respiratory syncytial virus subtypes A and B. Sci. Rep. 14, 14527 (2024).
Haynes, A. K. et al. Human metapneumovirus circulation in the United States, 2008 to 2014. Pediatrics 137, e20152927 (2016).
Koltai, M. et al. Determinants of RSV epidemiology following suppression through pandemic contact restrictions. Epidemics 40, 100614 (2022).
Jobe, N. B. et al. Human metapneumovirus seasonality and co-circulation with respiratory syncytial virus — United States, 2014–2024. Morb. Mortal. Wkly. Rep. 74, 182–187 (2025).
Metcalf, C. J. E. et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet 388, 728–730 (2016).
Mina, M. J. et al. A global immunological observatory to meet a time of pandemics. eLife 9, e58989 (2020).
Nguyen-Tran, H. et al. Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens. Lancet Microbe 3, e83–e85 (2022).
Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376 (2004).
He, D., Ionides, E. L. & King, A. A. Plug-and-play inference for disease dynamics: measles in large and small populations as a case study. J. R. Soc. Interface 7, 271–283 (2009).
Carpenter, B. et al. Stan: a probabilistic programming language. J. Stat. Softw. 76, 1–32 (2017).
Stan Development Team. RStan: the R interface to Stan https://mc-stan.org/ (2024).
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2024). https://www.R-project.org/
Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the effect of individual variation on disease emergence. Nature 438, 355–359 (2005).
Reis, J. & Shaman, J. Retrospective parameter estimation and forecast of respiratory syncytial virus in the United States. PLOS Comput. Biol. 12, e1005133 (2016).
Park, S. W. et al. Predicting the impact of COVID-19 non-pharmaceutical intervention on short- and medium-term dynamics of enterovirus D68 in the US. Epidemics 46, 100736 (2024).
Mossong, J. et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLOS Med. 5, e74 (2008).
